356 results on '"Leeming, Diana Julie"'
Search Results
52. Additional file 1 of LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
53. Additional file 1 of Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis
54. Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
55. Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells
56. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population
57. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
58. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
59. Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD
60. The Role of Extracellular Matrix Quality in Pulmonary Fibrosis
61. COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy
62. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma
63. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma
64. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients
65. Additional file 1 of Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis
66. A Fragment of Collagen Type VI alpha-3 chain is Elevated in Serum from Patients with Gastrointestinal Disorders
67. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients
68. Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis
69. Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk
70. Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk
71. A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients
72. Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C
73. Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery.
74. LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis.
75. Serologically assessed fragments of type VI collagen are predictors of progression free survival and death in patients with hepatocellular carcinoma
76. Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis
77. Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis
78. Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk
79. Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders
80. Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis
81. Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART
82. Type IV collagen turnover is predictive of mortality in COPD:a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort
83. Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model
84. A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.
85. Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients
86. Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
87. Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
88. Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders
89. Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C.
90. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis:Results from a randomized, placebo controlled trial
91. Mass-Spectrometry-Based Identification of Cross-Links in Proteins Exposed to Photo-Oxidation and Peroxyl Radicals Using 18O Labeling and Optimized Tandem Mass Spectrometry Fragmentation
92. Clinically validated markers of the extracellular matrix remodelling are altered by potential anti-fibrotic compounds in a human lung fibrosis ex vivo model
93. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
94. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease
95. Mass-Spectrometry-Based Identification of Cross-Links in Proteins Exposed to Photo-Oxidation and Peroxyl Radicals Using 18O Labeling and Optimized Tandem Mass Spectrometry Fragmentation
96. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C
97. A neo-epitope of serum lysyl oxidase like 2 (LOXL2) generated during enzyme maturation is elevated in cancer and idiopathic pulmonary disease
98. Is cardiovascular disease in patients with diabetes associated with serum levels of MMP-2, LOX, and the elastin degradation products ELM and ELM-2?
99. Extracellular matrix (ECM) protein fragments in serum and outcomes in two metastatic breast cancer cohorts.
100. Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.